These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17667809)

  • 1. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
    Stanca CM; Fiel MI; Kontorinis N; Agarwal K; Emre S; Schiano TD
    Transplantation; 2007 Jul; 84(2):180-6. PubMed ID: 17667809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
    Dumortier J; Scoazec JY; Chevallier P; Boillot O
    J Hepatol; 2004 Apr; 40(4):669-74. PubMed ID: 15030984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
    Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
    Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy.
    Babatin M; Schindel L; Burak KW
    Can J Gastroenterol; 2005 Jun; 19(6):359-65. PubMed ID: 15997269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
    Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
    Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
    Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
    Biselli M; Andreone P; Gramenzi A; Lorenzini S; Loggi E; Bonvicini F; Cursaro C; Bernardi M
    Dig Liver Dis; 2006 Jan; 38(1):27-32. PubMed ID: 16311084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
    Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation.
    Fiel MI; Shukla D; Saraf N; Xu R; Schiano TD
    Transpl Infect Dis; 2008 Jun; 10(3):184-9. PubMed ID: 17916116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
    Neumann U; Puhl G; Bahra M; Berg T; Langrehr JM; Neuhaus R; Neuhaus P
    Transplantation; 2006 Jul; 82(1):43-7. PubMed ID: 16861940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.